HIMS

Over the past six months, Hims & Hers Health, Inc. (HIMS) stock price has experienced significant fluctuations, with a decrease of 43.38% over the last 12 months and a year-to-date return of -8.20% as of October 5, 2026. On October 8, 2026, shares fell 5.0% to $28.06, reflecting a substantial drop of 51.8% over the past year. A late-July selloff pushed the stock to a low of $25.00, following an FTC lawsuit and a mixed second-quarter report. However, HIMS shares climbed approximately 12% over the 30 days leading up to October 9, 2026, rising from about $27.51 to $30.92, including a sharp +10% single-session gain on October 9, 2026, driven by renewed analyst commentary and positioning ahead of third-quarter results. Despite this rebound, the stock remained about 10% below its mid-July level, indicating persistent margin and regulatory concerns. The second-quarter 2026 results, reported on August 10, showed revenue up 38% year-over-year to $753.2 million, and subscribers increased by 19% to nearly 2.9 million, but the company reported a net loss of $86.3 million and a gross margin that narrowed to 64% from 76%. Management subsequently lifted full-year 2026 revenue guidance to $3.1 billion–$3.3 billion.